Brain Edema Pipeline Reviewed for Global Markets in H1 2016 Report

PUNE, India, July 1, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Brain Edema - Pipeline Review, H1 2016" market research report complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Edema and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Brain Edema with 18 market data tables and 12 figures, spread across 44 pages is available at http://www.rnrmarketresearch.com/brain-edema-pipeline-review-h1-2016-market-report.html .

The report also reviews key players involved in the therapeutic development for Brain Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Brain Edema Pipeline Review, H1 2016 report include FibroGen, Inc., Pharmazz, Inc. and Remedy Pharmaceuticals, Inc. Drug profiles discussed in this research report includes AER-271, Drugs to Modulate Aquaporin Channels for Brain Edema and Cancer, FG-4497, glyburide, PMZ-2123 and Small Molecules to Block Aquaporin-4 for Brain Edema.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Brain Edema and reviews pipeline therapeutics for Brain Edema by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Brain Edema therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Brain Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Brain Edema.